# Aptose Biosciences

Source: https://onco.cc/companies/aptose/  
OnCo record `aptose` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aptose is a San Diego and Toronto company developing tuspetinib, an oral kinase inhibitor acting on FLT3, SYK, JAK and other targets, for acute myeloid leukaemia in combination with venetoclax and azacitidine.

## Summary

Aptose Biosciences, listed on Nasdaq and the Toronto exchange, develops kinase inhibitors for blood cancers. Its lead, tuspetinib (HM43239), licensed from Hanmi, inhibits FLT3, SYK, JAK1/2 and other kinases and is being combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukaemia after single-agent responses in relapsed disease; an earlier candidate, luxeptinib, was deprioritised. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Aptose Biosciences Inc.; Aptose
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.aptose.com

## Sources

- Official website: https://www.aptose.com
- ClinicalTrials.gov: trials led by Aptose Biosciences: https://clinicaltrials.gov/search?lead=Aptose%20Biosciences

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [FLT3](https://onco.cc/targets/flt3/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/aptose.json